The European Medicines Agency (EMA) has issued a public assessment report (EPAR) for the drug Imdylltra, whose active substance is tarlatamab. This report summarizes the scientific evaluation of the medicine carried out by the Agency. The document has the status "Opinion", which indicates that it is the final version of the assessment. The EPAR provides information on the benefits and risks of Imdylltra, as well as its approved uses. The report is intended for the public and healthcare professionals. The goal of EPAR is to ensure the transparency of the process of drug evaluation in the European Union.